… an agreement to commercialize Viread for the treatment of chronic HBV infection in adults in … of first-line combination therapy with ambrisentan and tadalafil in subjects with PAH), will evaluate first-line … of resistant hypertension. In December, the Anti-Infective Drugs Advisory Committee of the U.S. Food and …
Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results

Share and Enjoy:
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks

Random Posts

Related posts:

  1. Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial … – Trading Markets (press release)
  2. InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results – MarketWatch (press release)
  3. InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results – MarketWatch (press release)